You are here: Industry Insights > Mylan

News List

Mylan partners with Revance Therapeutics to develop Botox biosimilar firstwordpharma
March 02, 2018
Under the deal, Mylan and Revance will work together to gain regulatory approval for the biosimilar product in the US, Europe and other markets.
Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace Cream biospace
January 02, 2018
Mylan now offers estradiol in four delivery methods，The approval showcases Mylan's ongoing investment in complex products
Mylan launches DURART R 450 expressbpd
November 17, 2017
Mylan has serious concerns about Teva’s ability to integrate and efficiently run a combined company, and deliver meaningful shareholder value, he said, adding “there is simply no track record for investors to find”. (Reuters)
Theravance Biopharma, Mylan Submit NDA for Revefenacin americanpharmaceuticacreview
November 14, 2017
The NDA is supported by the companies' Phase 3 program for revefenacin, which consisted of two replicate pivotal Phase 3 efficacy studies and a 12-month, open-label, active comparator safety study.
Mylan to withdraw from Tel Aviv Stock Exchange pharmafile
November 14, 2017
US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement for the first time since it entered it in November 2015.
Mylan seeks EMA approval for two biosimilars expressbpd
November 08, 2017
Mylan has serious concerns about Teva’s ability to integrate and efficiently run a combined company, and deliver meaningful shareholder value, he said, adding “there is simply no track record for investors to find”. (Reuters)
Sanofi launches patent infringement lawsuit against Mylan over diabetes pen pharmafile.
October 26, 2017
Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 of the French drugmaker’s patents, in particular its disposable insulin glargine pre-filled pen Lantus as well as vial-drug diabetes products.
Mylan and Natsimbio in agreement for production of anti-HIV drugs in Russia expressbpd
September 30, 2017
Mylan India is in an agreement with Natsimbio, Russian vaccines producer, for supply of its active substances to produce anti-HIV drugs in Russia.
Indivior reaches settlement with Mylan over patent dispute pharmafile
September 26, 2017
Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by agreeing to an undisclosed settlement with the company.
Nacimbio signs agreement with MYLAN Laboratories biospectrumasia
September 20, 2017
Within the framework of the license agreement, there will be transfer of technology for the production of both ready-made forms and active pharmaceutical substances for the creation of modern combined drugs for the treatment of HIV infection

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page